|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
17.11.25 - 14:03
|
Broken String Biosciences Announces New Leadership to Drive Commercialization of INDUCE-seq® Platform for Gene Editing On- and Off-target Characterization (Business Wire)
|
|
|
CAMBRIDGE, England--(BUSINESS WIRE)--Broken String Biosciences (“Broken String”), a leader in advancing gene editing safety, today announced the appointment of new leadership to drive the commercialization of its INDUCE-seq® platform, now available to cell and gene therapy developers worldwide.
To drive the company's commercial expansion, Terry Pizzie has been appointed as CEO, bringing extensive experience from leading and scaling global life science businesses. Mr. Pizzie has previously held leadership positions, including CEO of Horizon Discovery and Astrea Bioseparations, where he guided both companies through successful growth and exits, as well as senior roles at Pacific Biosciences, GE Healthcare, Applied Biosystems, and Genetix. His appointment marks a significant milestone as Broken String transitions from a pioneering technology developer to a fully commercial organization.
The company's next stage of growth is focused on scaling access to INDUCE-seq®, a proprietary platform that directl...
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
